JP2022552314A5 - - Google Patents
Info
- Publication number
- JP2022552314A5 JP2022552314A5 JP2022521958A JP2022521958A JP2022552314A5 JP 2022552314 A5 JP2022552314 A5 JP 2022552314A5 JP 2022521958 A JP2022521958 A JP 2022521958A JP 2022521958 A JP2022521958 A JP 2022521958A JP 2022552314 A5 JP2022552314 A5 JP 2022552314A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- cells
- domain
- chimeric antigen
- cd28h
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025063708A JP7861191B2 (ja) | 2019-10-17 | 2025-04-08 | 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962916468P | 2019-10-17 | 2019-10-17 | |
| US62/916,468 | 2019-10-17 | ||
| USPCT/US2020/054601 | 2020-10-07 | ||
| PCT/US2020/054601 WO2021071962A1 (en) | 2019-10-07 | 2020-10-07 | Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof |
| PCT/US2020/056387 WO2021077117A1 (en) | 2019-10-17 | 2020-10-19 | Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025063708A Division JP7861191B2 (ja) | 2019-10-17 | 2025-04-08 | 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022552314A JP2022552314A (ja) | 2022-12-15 |
| JP2022552314A5 true JP2022552314A5 (OSRAM) | 2023-10-27 |
| JP7664913B2 JP7664913B2 (ja) | 2025-04-18 |
Family
ID=75537569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022521958A Active JP7664913B2 (ja) | 2019-10-17 | 2020-10-19 | 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240226293A9 (OSRAM) |
| EP (1) | EP4045539A4 (OSRAM) |
| JP (1) | JP7664913B2 (OSRAM) |
| CN (1) | CN114901693A (OSRAM) |
| WO (1) | WO2021077117A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| TW202237827A (zh) | 2020-12-03 | 2022-10-01 | 美商世紀治療股份有限公司 | 經基因工程改造之細胞及其用途 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| US11473060B2 (en) | 2020-12-30 | 2022-10-18 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into NK cells |
| AU2022277688A1 (en) * | 2021-05-20 | 2023-12-21 | Synteny Therapeutics, Inc. | Genomic safe harbors |
| JP2024542159A (ja) * | 2021-11-04 | 2024-11-13 | アーティバ バイオセラピューティクス インコーポレイテッド | Ｎｋ細胞と多重特異性エンゲージャーとによるがんの処置 |
| EP4429681A4 (en) * | 2021-11-08 | 2025-12-10 | Fate Therapeutics Inc | MODIFIED EFFECTOR CELLS AND METHODS FOR IMPROVING OMNI-PRESENT TUMOR TARGETING |
| CN116103239A (zh) * | 2021-11-11 | 2023-05-12 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
| WO2023137344A1 (en) * | 2022-01-11 | 2023-07-20 | Celularity Inc. | Cleavage resistant cd16 constructs and uses thereof |
| JP7707304B2 (ja) | 2022-04-08 | 2025-07-14 | フェイト セラピューティクス，インコーポレイティド | 腫瘍標的化のためのキメラ抗原受容体 |
| KR20250005097A (ko) | 2022-04-08 | 2025-01-09 | 페이트 세러퓨틱스, 인코포레이티드 | 고형 종양 표적화 골격을 갖는 세포 및 이의 용도 |
| WO2024140778A1 (zh) * | 2022-12-27 | 2024-07-04 | 科济生物医药（上海）有限公司 | Nkg2d工程化细胞及其组合物 |
| CN116445414B (zh) * | 2023-03-03 | 2025-07-08 | 广州瑞臻再生医学科技有限公司 | 基因修饰多潜能干细胞衍生的增强型nk细胞的方法及其应用 |
| CN117285651B (zh) * | 2023-09-27 | 2025-06-06 | 中国医学科学院北京协和医院 | 靶向c-MET的嵌合抗原受体、CAR-M及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050113564A1 (en) * | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| JP6849600B6 (ja) * | 2015-01-29 | 2021-06-30 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | キメラ抗原受容体、組成物及び方法 |
| CN108368520B (zh) * | 2015-11-04 | 2023-01-17 | 菲特治疗公司 | 多能细胞的基因组工程改造 |
| WO2017078807A1 (en) * | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| WO2018132506A1 (en) * | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
| BR112020010597A2 (pt) * | 2017-12-08 | 2020-10-27 | Fate Therapeutics, Inc. | imunoterapias com o uso de células efetoras derivadas de ipsc intensificadas |
| KR20250048610A (ko) * | 2017-12-22 | 2025-04-09 | 페이트 세러퓨틱스, 인코포레이티드 | 향상된 면역 효과기 세포 및 이의 용도 |
| WO2019191495A1 (en) * | 2018-03-29 | 2019-10-03 | Fate Therapeutics, Inc. | Engineered immune effector cells and use thereof |
| BR112022017512A2 (pt) * | 2020-03-26 | 2022-10-18 | Us Health | Receptores de antígeno quiméricos contendo domínio cd28h e métodos de uso dos mesmo |
-
2020
- 2020-10-19 JP JP2022521958A patent/JP7664913B2/ja active Active
- 2020-10-19 WO PCT/US2020/056387 patent/WO2021077117A1/en not_active Ceased
- 2020-10-19 US US17/769,651 patent/US20240226293A9/en active Pending
- 2020-10-19 CN CN202080090875.9A patent/CN114901693A/zh active Pending
- 2020-10-19 EP EP20877752.4A patent/EP4045539A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022550899A5 (OSRAM) | ||
| JP2022541441A5 (OSRAM) | ||
| JP2021505131A5 (OSRAM) | ||
| JP2022548943A5 (OSRAM) | ||
| JP2021519061A5 (OSRAM) | ||
| JP2022176327A (ja) | タグ化キメラエフェクター分子およびそのレセプター | |
| JP2022510207A5 (OSRAM) | ||
| JP2023505206A5 (OSRAM) | ||
| JP2024518011A (ja) | 多様な免疫細胞のための単鎖および多鎖合成抗原受容体 | |
| US11845804B2 (en) | CAR-CD30 T cells for treatment of CD30+ tumors | |
| JP7566628B2 (ja) | キメラ抗原受容体を発現する免疫細胞 | |
| US11065278B2 (en) | Method and compositions for cellular immunotherapy | |
| JP2023530704A5 (OSRAM) | ||
| JP2023548467A5 (OSRAM) | ||
| Murad et al. | Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies | |
| JP2023548829A5 (OSRAM) | ||
| JP2018532432A5 (OSRAM) | ||
| US12187776B2 (en) | Pooling signaling and costimulatory domains in B7H6 chimeric antigen receptor | |
| JP2021536265A5 (OSRAM) | ||
| JP2023501722A5 (OSRAM) | ||
| WO2018002358A1 (en) | Improved adoptive t-cell therapy | |
| GB2607452A (en) | Anti-TCR antibody molecules and uses thereof | |
| JP2025105605A5 (OSRAM) | ||
| KR20230137923A (ko) | 신규한 키메라 항원 수용체 및 이의 용도 | |
| JP2024510900A5 (OSRAM) |